In 2011, ipilimumab, the first immune checkpoint inhibitor, was approved, followed by the emergence of PD-1/PD-L1 inhibitors, which significantly prolonged survival in various cancer patients and ushered in a new era of tumor immunotherapy (79). Here, CD274 is linked to neoplasm.